American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Ethylene Glycol Poisoning. Ad Hoc Committee.
American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Ethylene Glycol Poisoning. Ad Hoc Committee.
复制标题
美国临床毒理学会乙二醇中毒治疗实践指南。
DOI:
10.1081/clt-100102445
复制
发表时间:
1999
期刊:
影响因子:
--
通讯作者:
W. Watson
中科院分区:
文献类型:
--
作者:
Heather D. Miller;D. Barceloux;E. Krenzelok;K. Olson;W. Watson
Fomepizole (4-methylpyrazole, 4-MP, Antizol) is a potent inhibitor of alcohol dehydrogenase that was approved recently by the US Food and Drug Administration (FDA) for the treatment of ethylene glycol poisoning. Although ethanol is the traditional antidote for ethylene glycol poisoning, it has not been studied prospectively. Furthermore, the FDA has not approved the use of ethanol for this purpose. Case reports and a prospective case series indicate that the intravenous (i.v.) administration of fomepizole every 12 hours prevents renal damage and metabolic abnormalities associated with the conversion of ethylene glycol to toxic metabolites. Currently, there are insufficient data to define the relative role of fomepizole and ethanol in the treatment of ethylene glycol poisoning. Fomepizole has clear advantages over ethanol in terms of validated efficacy, predictable pharmacokinetics, ease of administration, and lack of adverse effects, whereas ethanol has clear advantages over fomepizole in terms of long-term clinical experience and acquisition cost. The overall comparative cost of medical treatment using each antidote requires further study.
DOI:
10.1016/0006-291x(85)90295-5
发表时间:
1985
影响因子:
3.1
作者:
Feierman,DE;Cederbaum,AI
通讯作者:
Cederbaum,AI
影响因子:
6.1
作者:
Chow,HH;Hutchaleelaha,A;Mayersohn,M
通讯作者:
Mayersohn,M
DOI:
10.1111/j.1530-0277.1996.tb05255.x
发表时间:
1996
期刊:
Alcoholism, clinical and experimental research
影响因子:
--
作者:
Jacobsen,D;Sebastian,CS;Dies,DF;Breau,RL;Spann,EG;Barron,SK;McMartin,KE
通讯作者:
McMartin,KE